Validation of high-performance liquid chromatographic method for analysis of fluconazole in microemulsions and liquid crystals

The Optimized HPLC Method for Quantitative Analysis of Phenylethyl Resorcinol Loaded in the Novel Vesicle Carriers and Permeated in In Vitro Skin Permeation Study

The high performance liquid chromatography (HPLC) was used for quantitative determination of phenylethyl resorcinol (PR) which was loaded in the novel vesicle carriers including ethosome, invasome and transfersome formulations, and permeated into pig skin membrane and receptor fluid for skin permeation study. The reverse-phase chromatography was carried out with a C18 column (150 × 4.6 mm2, 5 μm, HypersilTM, Thermo Fisher Scientific Inc, USA) with the column temperature at 25°C. A mixture of acetonitrile-methanol-Milli-Q water in the ratio of 40:20:40%, v/v/v was used as a mobile phase by maintaining the flow rate at 0.8 mL/min. The 20 μL sample solution was injected and the absorbance was detected at 254 nm using an HPLC Agilent 1100 series. This method gave the chromatogram with symmetric peak of PR at the appropriate retention time of 4.620 min. At such retention time no interfering peaks were detected from other matrix components. All %recovery and %RSD values of PR analysis were in the range of 98-102% and not more than 2.0%, respectively. From the validation data, the method demonstrated that it had satisfactory specificity, sensitivity, linearity, accuracy and precision appropriate for analysis of PR in the presence of vesicle carriers and skin permeation study.

Phenobarbital loaded microemulsion: development, kinetic release and quality control

ABSTRACT This study aimed to obtain and characterize a microemulsion (ME) containing phenobarbital (PB). The PB was incorporated in the proportion of 5% and 10% in a microemulsion system containing Labrasol(r), ethanol, isopropyl myristate and purified water. The physicochemical characterization was performed and the primary stability of the ME was evaluated. An analytical method was developed using spectrophotometry in UV = 242 nm. The kinetics of the in vitro release (Franz model) of the ME and the emulsion (EM) containing PB was evaluated. The incorporation of PB into ME at concentrations of 5 and 10% did not change pH and resistance to centrifugation. There was an increase in particle size, a decrease of conductivity and a change in the refractive index in relation to placebo ME. The ME remained stable in preliminary stability tests. The analytical method proved to be specific, linear, precise, accurate and robust. Regarding the kinetics of the in vitro release, ME obtained an in vitro release profile greater than the EM containing PB. Thus, the obtained ME has a potential for future transdermal application, being able to compose a drug delivery system for the treatment of epilepsy.